C-Path’s 2023 Neuroscience Program Annual Meeting is set for Thursday, November 30 in Washington D.C. Bringing stakeholders together from both the Critical Path for Alzheimer’s Disease and the Critical Path for Parkinson’s consortia, this meeting will build off the recent advancements in drug development for Parkinson’s and Alzheimer’s, exploring important opportunities to apply lessons from successes in both therapeutic areas.
The key objectives of the meeting are to:
- Examine the state of markers of disease modification across the disease continuum, with an emphasis on early disease stages (and how to optimize their definition), in AD and PD.
- Contextualize clinical meaningfulness across the disease continuum in AD and PD by incorporating the patient voice.
- Prioritize which drug development tools are needed to accelerate development of disease modifying treatments in partnership with industry and drug development experts.
